Fig. 3

Effects of PTX treatment on DCs and T cells in vivo. a β-Galactosidase expression on D3 post-immunization in CD11c⁺DCs from the spleens of Axin2-reporter mice immunized with IRBP-CFA and injected intraperitoneally with PTX or PBS at day 0 and day 2 detected using FACS (n = 3). b–d WT mice were immunized with IRBP-CFA and injected intraperitoneally with PTX or PBS at day 0 and day 2. b Expression of MHC Class II, CD80, and CD86 in CD11c⁺ DCs sorted from the spleen on D3 post-immunization measured using FACS (n = 3). c, d Expression levels of inflammatory factors expressed in or secreted by CD11c⁺ DCs from the spleen at D3 post-immunization after 24 h of culture and 60 min of ATP stimulation detected using qPCR or ELISA (n = 5). e–h WT mice were immunized with IRBP-CFA and injected with PTX or PBS at day 0 and day 2. e Representative FACS plot showing the expression of IFN-γ and IL-17A in draining lymph node (DLN)-derived CD4⁺ T cells on D5 post-immunization (n = 5). f Percentages of the Th1 and Th17 cell subpopulations in DLN-CD4⁺ T cells (n = 5). g Representative FACS plot showing the expression of Foxp3 in DLN-derived CD4⁺ T cells on D5 post-immunization (n = 5). h Percentages of Treg cell subpopulations among DLN-CD4⁺ T cells (n = 5). The data shown are representative of three independent experiments. Data are presented as the mean ± SD. NS, p > 0.05, *p < 0.05, **p < 0.01